Canakinumab

In the US, Canakinumab (canakinumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome and Muckle Wells Syndrome.

US matches:

• Canakinumab


• Canakinumab Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AC08

CAS registry number (Chemical Abstracts Service)

0914613-48-2

Chemical Formula

C6452-H9958-N1722-O2010-S42

Therapeutic Category

Immunosuppressant

Foreign Names

• Canakinumabum (Latin)
• Canakinumab (German)
• Canakinumab (French)
• Canakinumab (Spanish)

Generic Names

• Canakinumab (OS: USAN)
• ACZ885 (IS)
• UNII-37CQ2C7X93 (IS)

Brand Names

• Ilaris
  Novartis, Switzerland; Novartis, Germany; Novartis, France; Novartis, United Kingdom; Novartis, Sweden; Novartis, United States

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.